These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25557638)

  • 1. Quantitative muscle ultrasonography in the follow-up of juvenile dermatomyositis.
    Habers GE; Van Brussel M; Bhansing KJ; Hoppenreijs EP; Janssen AJ; Van Royen-Kerkhof A; Pillen S
    Muscle Nerve; 2015 Oct; 52(4):540-6. PubMed ID: 25557638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM).
    Abdul-Aziz R; Yu CY; Adler B; Bout-Tabaku S; Lintner KE; Moore-Clingenpeel M; Spencer CH
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):25. PubMed ID: 28403889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative muscle ultrasound: a potential tool for assessment of disease activity in juvenile dermatomyositis.
    Bhansing KJ; Hoppenreijs EP; Janssen AJ; van Royen-Kerkhof A; Nijhuis-Van der Sanden MW; van Riel PL; Pillen S
    Scand J Rheumatol; 2014; 43(4):339-41. PubMed ID: 24720507
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis.
    Maillard SM; Jones R; Owens C; Pilkington C; Woo P; Wedderburn LR; Murray KJ
    Rheumatology (Oxford); 2004 May; 43(5):603-8. PubMed ID: 14983103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.
    McCann LJ; Garay SM; Ryan MM; Harris R; Riley P; Pilkington CA
    Rheumatology (Oxford); 2007 Aug; 46(8):1363-6. PubMed ID: 17569746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
    Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
    Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Submaximal Exercise Capacity in Juvenile Dermatomyositis after Longterm Disease: The Contribution of Muscle, Lung, and Heart Involvement.
    Berntsen KS; Tollisen A; Schwartz T; Kirkhus E; Aaløkken TM; Lund MB; Flatø B; Sjaastad I; Sanner H
    J Rheumatol; 2017 Jun; 44(6):827-834. PubMed ID: 28365577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis.
    Quiñones R; Morgan GA; Amoruso M; Field R; Huang CC; Pachman LM
    Arthritis Care Res (Hoboken); 2013 Oct; 65(10):1697-701. PubMed ID: 23666925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
    Lovell DJ; Lindsley CB; Rennebohm RM; Ballinger SH; Bowyer SL; Giannini EH; Hicks JE; Levinson JE; Mier R; Pachman LM; Passo MH; Perez MD; Reed AM; Schikler KN; Smith M; Zemel LS; Rider LG
    Arthritis Rheum; 1999 Oct; 42(10):2213-9. PubMed ID: 10524696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study.
    Jacobs J; Jansen M; Janssen H; Raijmann W; Van Alfen N; Pillen S
    Muscle Nerve; 2013 Jun; 47(6):856-63. PubMed ID: 23519831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary validation of muscle ultrasound in juvenile dermatomyositis (JDM).
    Mamyrova G; McBride E; Yao L; Shrader JA; Jain M; Yao J; Curiel RV; Miller FW; Harris-Love MO; Rider LG
    Rheumatology (Oxford); 2022 Apr; 61(SI):SI48-SI55. PubMed ID: 34791066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study.
    Sanner H; Kirkhus E; Merckoll E; Tollisen A; Røisland M; Lie BA; Taraldsrud E; Gran JT; Flatø B
    Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1103-11. PubMed ID: 20506141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in juvenile dermatomyositis: a case series.
    Dagher R; Desjonquères M; Duquesne A; Quartier P; Bader-Meunier B; Fischbach M; Guiguonis V; Picherot G; Cimaz R
    Rheumatol Int; 2012 Mar; 32(3):711-6. PubMed ID: 21152922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.
    Mathiesen PR; Buchvald F; Nielsen KG; Herlin T; Friis T; Nielsen S
    Rheumatology (Oxford); 2014 Apr; 53(4):644-9. PubMed ID: 24310298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid related protein induces muscle derived inflammatory mediators in juvenile dermatomyositis.
    Nistala K; Varsani H; Wittkowski H; Vogl T; Krol P; Shah V; Mamchaoui K; Brogan PA; Roth J; Wedderburn LR
    Arthritis Res Ther; 2013 Sep; 15(5):R131. PubMed ID: 24286299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne muscular dystrophy.
    Jansen M; van Alfen N; Nijhuis van der Sanden MW; van Dijk JP; Pillen S; de Groot IJ
    Neuromuscul Disord; 2012 Apr; 22(4):306-17. PubMed ID: 22133654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis.
    Gitiaux C; De Antonio M; Aouizerate J; Gherardi RK; Guilbert T; Barnerias C; Bodemer C; Brochard-Payet K; Quartier P; Musset L; Chazaud B; Desguerre I; Bader-Meunier B
    Rheumatology (Oxford); 2016 Mar; 55(3):470-9. PubMed ID: 26424834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome in patients with juvenile dermatomyositis: A case series.
    Chevalier G; Fakih O; Lhose A; Ballot-Schmit C; Prati C; Puzenat E; Aubin F
    Arch Pediatr; 2021 Aug; 28(6):475-479. PubMed ID: 34034928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical signs and symptoms in a joint model of four disease activity parameters in juvenile dermatomyositis: a prospective, longitudinal, multicenter cohort study.
    van Dijkhuizen EHP; De Iorio M; Wedderburn LR; Deakin CT;
    Arthritis Res Ther; 2018 Aug; 20(1):180. PubMed ID: 30111380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
    Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.